244 related articles for article (PubMed ID: 29527667)
1. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.
Castillo JJ; Guerrero-Garcia T; Baldini F; Tchernonog E; Cartron G; Ninkovic S; Cwynarski K; Dierickx D; Tousseyn T; Lansigan F; Linnik Y; Mogollon R; Navarro JT; Olszewski AJ; Reagan JL; Fedele P; Gilbertson M; Grigoriadis G; Bibas M
Br J Haematol; 2019 Feb; 184(4):679-682. PubMed ID: 29527667
[No Abstract] [Full Text] [Related]
2. Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma.
Fedele PL; Gregory GP; Gilbertson M; Shortt J; Kumar B; Opat S; Grigoriadis G
Ann Hematol; 2016 Mar; 95(4):667-8. PubMed ID: 26801792
[No Abstract] [Full Text] [Related]
3. Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis.
Dittus C; Grover N; Ellsworth S; Tan X; Park SI
Leuk Lymphoma; 2018 Sep; 59(9):2121-2127. PubMed ID: 29303024
[TBL] [Abstract][Full Text] [Related]
4. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
[TBL] [Abstract][Full Text] [Related]
5. Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma.
Arora N; Gupta A; Sadeghi N
BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 28993364
[TBL] [Abstract][Full Text] [Related]
6. [HIV-negative plasmablastic lymphoma attaining sustained remission with bortezomib-combined dose-adjusted EPOCH therapy].
Kobayashi H; Miyagi N
Rinsho Ketsueki; 2017; 58(5):443-448. PubMed ID: 28592757
[TBL] [Abstract][Full Text] [Related]
7. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.
Till BG; Li H; Bernstein SH; Fisher RI; Burack WR; Rimsza LM; Floyd JD; DaSilva MA; Moore DF; Pozdnyakova O; Smith SM; LeBlanc M; Friedberg JW
Br J Haematol; 2016 Jan; 172(2):208-18. PubMed ID: 26492567
[TBL] [Abstract][Full Text] [Related]
9. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.
Little RF; Pittaluga S; Grant N; Steinberg SM; Kavlick MF; Mitsuya H; Franchini G; Gutierrez M; Raffeld M; Jaffe ES; Shearer G; Yarchoan R; Wilson WH
Blood; 2003 Jun; 101(12):4653-9. PubMed ID: 12609827
[TBL] [Abstract][Full Text] [Related]
10. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC
Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422
[TBL] [Abstract][Full Text] [Related]
11. Bleomycin-Induced Flagellate Dermatitis.
Turan Erkek E; Karaali CN; Yılmaz G; Gültürk E
Turk J Haematol; 2019 May; 36(2):138-140. PubMed ID: 30600679
[No Abstract] [Full Text] [Related]
12. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
Romaguera JE; Wang M; Feng L; Fayad LE; Hagemeister F; McLaughlin P; Rodriguez MA; Fanale M; Orlowski R; Kwak LW; Neelapu S; Oki Y; Pro B; Younes A; Samaniego F; Fowler N; Hartig K; Valentinetti M; Smith J; Ford P; Naig A; Medeiros LJ; Kantarjian HM; Goy A
Cancer; 2018 Jun; 124(12):2561-2569. PubMed ID: 29723393
[TBL] [Abstract][Full Text] [Related]
14. Anti-cancer agents. Unique protocol looks promising for lymphoma.
TreatmentUpdate; 2003; 15(4):5-7. PubMed ID: 17216853
[No Abstract] [Full Text] [Related]
15. Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Leonard JP; Kolibaba KS; Reeves JA; Tulpule A; Flinn IW; Kolevska T; Robles R; Flowers CR; Collins R; DiBella NJ; Papish SW; Venugopal P; Horodner A; Tabatabai A; Hajdenberg J; Park J; Neuwirth R; Mulligan G; Suryanarayan K; Esseltine DL; de Vos S
J Clin Oncol; 2017 Nov; 35(31):3538-3546. PubMed ID: 28862883
[TBL] [Abstract][Full Text] [Related]
16. A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution.
Huang JJ; Xia Y; Wang Y; Liu PP; Bi XW; Sun P; Lin TY; Jiang WQ; Li ZM
Oncotarget; 2016 Jul; 7(27):41242-41250. PubMed ID: 27183909
[TBL] [Abstract][Full Text] [Related]
17. [Doxorubicin and etoposide-besed combination chemotherapy regimen for peripheral T-cell lymphoma].
Zheng W; Zhu J; Xie Y
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):875-6. PubMed ID: 19173838
[No Abstract] [Full Text] [Related]
18. Long-term outcomes of patients with newly diagnosed extranodal natural killer/T-cell lymphoma treated by etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen: a single-institution experience.
Huang H; Lin Z; Lin X; Cai Q; Xia Z; Jiang W
Leuk Lymphoma; 2011 Jun; 52(6):1041-8. PubMed ID: 21599590
[TBL] [Abstract][Full Text] [Related]
19. Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy.
Floeter AE; Patel A; Tran M; Chamberlain MC; Hendrie PC; Gopal AK; Cassaday RD
Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):225-230. PubMed ID: 28169156
[TBL] [Abstract][Full Text] [Related]
20. Low-intensity therapy in adults with Burkitt's lymphoma.
Dunleavy K; Pittaluga S; Shovlin M; Steinberg SM; Cole D; Grant C; Widemann B; Staudt LM; Jaffe ES; Little RF; Wilson WH
N Engl J Med; 2013 Nov; 369(20):1915-25. PubMed ID: 24224624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
